Healthcare · Pharmaceuticals & Biotechnology
QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #51 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 23 Dec 2025 | Mr. Gagan Harsh Sharma | Promoter | Buy | 0 | ₹0 |
| 18 Dec 2025 | Mr. Gagan Harsh Sharma | Promoter | Buy | 0 | ₹0 |
| 18 Dec 2025 | Mr. Gagan Harsh Sharma | Promoter | Buy | 0 | ₹0 |
| 1 Jul 2025 | Gagan Harsh Sharma | Promoter | Buy | 0 | ₹0 |
| 1 Jul 2025 | Gagan Harsh Sharma | Promoter | Buy | 0 | ₹0 |
| 1 Jul 2025 | Gagan Harsh Sharma | Promoter | Buy | 0 | ₹0 |
| 26 Jun 2025 | Mr. Gagan Harsh Sharma | Promoter | Buy | 0 | ₹0 |
| 26 Jun 2025 | Mr. Gagan Harsh Sharma | Promoter | Buy | 0 | ₹0 |
| 12 Jun 2025 | Mr. Gagan Harsh Sharma | Promoter | Buy | 0 | ₹0 |
| 12 Jun 2025 | Mr. Gagan Harsh Sharma | Promoter | Buy | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 28 Sep 2026 | ANUPAM RASAYAN INDIA LIMITED | Bulk | Buy | 2,250,000 | 723.2900 | NSE |
| 28 Sep 2026 | ANUPAM RASAYAN INDIA LIMITED | Bulk | Buy | 2,250,000 | 723.2900 | NSE |
| 28 Sep 2026 | ANUPAM RASAYAN INDIA LIMITED | Bulk | Buy | 2,250,000 | 723.2900 | NSE |
| 21 Jul 2026 | NOVA VIDA LIMITED | Block | Buy | 700,000 | 485.0000 | NSE |
| 21 Jul 2026 | ARIAN INVESTMENT LTD | Block | Sell | 700,000 | 485.0000 | NSE |
| 21 Jul 2026 | NOVA VIDA LIMITED | Bulk | Buy | 700,000 | 485.0000 | NSE |
| 21 Jul 2026 | ARIAN INVESTMENT LTD | Bulk | Sell | 700,000 | 485.0000 | NSE |
| 29 Jun 2026 | MATEUS LTD | Block | Buy | 1,150,000 | 490.0000 | NSE |
| 29 Jun 2026 | ARIAN INVESTMENT LTD | Block | Sell | 1,150,000 | 490.0000 | NSE |
| 29 Jun 2026 | MATEUS LTD | Bulk | Buy | 1,150,000 | 490.0000 | NSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 8 Jul 2026 | Dividend - Re 1 Per Share | 1.0000 | 8 Jul 2026 |
| 18 Feb 2026 | Interim Dividend - Re 0.50 Per Share | 0.5000 | 18 Feb 2026 |
| 24 Jul 2025 | Annual General Meeting/Dividend - Rs 0.50 Per Share | 0.5000 | 24 Jul 2025 |
| 18 Jul 2024 | Annual General Meeting/Dividend - Rs 0.50 Per Share | 0.5000 | — |
| 12 Jul 2023 | Annual General Meeting/Dividend - Re 0.50 Per Share | 0.5000 | — |
| 20 Jun 2022 | Annual General Meeting/ Dividend - Rs 0.50 Per Share | 0.5000 | — |
| 13 Sep 2021 | Annual General Meeting/Dividend - Rs 0.50 Per Share | 0.5000 | — |
| 17 Sep 2020 | Annual General Meeting/Dividend - Rs 0.50 Per Share | 0.5000 | — |
| 12 Sep 2019 | Annual General Meeting/Dividend - Re 1 Per Share | 1.0000 | — |
| 14 Aug 2018 | Annual General Meeting/Dividend- Re 1 Per Share | 1.0000 | — |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| — | NAME_CHANGE | Name changed from Bliss Chemicals & Pharmaceuticals India Ltd. to Bliss GVS Pharma Limited |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 1 Oct 2026 | Fund Raising/Other business matters | — |
| 12 Aug 2026 | Financial Results/Other business matters | Yes |
| 12 May 2026 | Financial Results/Dividend/Other business matters | Yes |
| 10 Feb 2026 | Financial Results/Dividend | Yes |
| 6 Nov 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 1 Oct 2026 | Board Meeting | Bliss GVS Pharma Ltd - 506197 - Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") |
| 1 Oct 2026 | Insider Trading / SAST | Bliss GVS Pharma Ltd - 506197 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 |
| 1 Oct 2026 | Outcome of Board Meeting | Bliss GVS Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 01, 2026. |
| 29 Sep 2026 | Trading Window | Bliss GVS Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 29 Sep 2026 | Resignation of Director/KMP/SMP | Bliss GVS Pharma Limited has informed the Exchange about Resignation of Director/KMP/SMP |
| 29 Sep 2026 | Insider Trading / SAST | Bliss GVS Pharma Ltd - 506197 - Closure of Trading Window |
| 28 Sep 2026 | Board Meeting | Bliss GVS Pharma Ltd - 506197 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday, October 01, 2026 |
| 28 Sep 2026 | Company Update | Bliss GVS Pharma Ltd - 506197 - Announcement under Regulation 30 (LODR)-Change in Management Control |
| 28 Sep 2026 | Outcome of Board Meeting | Bliss GVS Pharma Limited has informed the Exchange regarding Outcome of the 2nd Board Meeting held on September 28, 2026 at shorter Notice regarding re-classification from the "Promoter and Promoter Group" category to the "public" category. |
| 28 Sep 2026 | Change in Management | Bliss GVS Pharma Limited has informed the Exchange about change in Management pursuant to the Change in Control of the Company. |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
